Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031
Debt
Debt-to-Equity Ratio0.30
Current Ratio1.21
Quick Ratio1.21
Price-To-Earnings
Trailing P/E Ratio53.17
Forward P/E Ratio34.28
P/E Growth1.79
Sales & Book Value
Annual Sales$1.53 billion
Price / Sales2.43
Cash Flow$2.8433 per share
Price / Cash41.23
Book Value$15.22 per share
Price / Book7.70
Profitability
EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins4.46%
Return on Equity20.11%
Return on Assets12.46%
Miscellaneous
Employees17,900
Outstanding Shares31,840,000
Market Cap$3.63 billion
Amedisys (NASDAQ:AMED) Frequently Asked Questions
What is Amedisys' stock symbol?
Amedisys trades on the NASDAQ under the ticker symbol "AMED."
How were Amedisys' earnings last quarter?
Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings data on Tuesday, July, 31st. The health services provider reported $1.00 EPS for the quarter, topping the Zacks' consensus estimate of $0.78 by $0.22. The health services provider earned $411.60 million during the quarter, compared to the consensus estimate of $403.62 million. Amedisys had a return on equity of 20.11% and a net margin of 4.46%. During the same period in the previous year, the company posted $0.62 earnings per share. View Amedisys' Earnings History.
When is Amedisys' next earnings date?
What guidance has Amedisys issued on next quarter's earnings?
Amedisys issued an update on its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share (EPS) guidance of $3.32-3.41 for the period, compared to the Thomson Reuters consensus estimate of $3.11. The company issued revenue guidance of $1.63-1.65 billion, compared to the consensus revenue estimate of $1.63 billion.
What price target have analysts set for AMED?
11 brokers have issued 12-month price targets for Amedisys' shares. Their forecasts range from $56.00 to $115.00. On average, they expect Amedisys' share price to reach $76.80 in the next year. This suggests that the stock has a possible downside of 34.5%. View Analyst Price Targets for Amedisys.
What is the consensus analysts' recommendation for Amedisys?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.
Are investors shorting Amedisys?
Amedisys saw a drop in short interest in July. As of July 31st, there was short interest totalling 705,661 shares, a drop of 28.5% from the July 13th total of 987,261 shares. Based on an average trading volume of 328,062 shares, the short-interest ratio is presently 2.2 days. Approximately 2.3% of the shares of the company are sold short. View Amedisys' Current Options Chain.
Who are some of Amedisys' key competitors?
Who are Amedisys' key executives?
Amedisys' management team includes the folowing people:
- Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 57)
- Mr. Scott G. Ginn, Chief Financial Officer (Age 49)
- Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
- Mr. Michael P. North, Chief Information Officer (Age 53)
- Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems
Has Amedisys been receiving favorable news coverage?
Press coverage about AMED stock has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amedisys earned a media and rumor sentiment score of 0.07 on Accern's scale. They also gave news coverage about the health services provider an impact score of 46.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Amedisys.
Who are Amedisys' major shareholders?
Amedisys' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.90%), KKR CREDIT ADVISORS (US) LLC (7.60%), Dimensional Fund Advisors LP (3.50%), American Century Companies Inc. (3.30%), Wells Fargo & Company MN (2.85%) and Voya Investment Management LLC (2.23%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.
Which institutional investors are selling Amedisys stock?
AMED stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Voya Investment Management LLC, FMR LLC, Bank of New York Mellon Corp, Wells Fargo & Company MN, Tygh Capital Management Inc., Dimensional Fund Advisors LP and OppenheimerFunds Inc.. Company insiders that have sold Amedisys company stock in the last year include David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.
Which institutional investors are buying Amedisys stock?
AMED stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Sei Investments Co., Pier Capital LLC, DE Burlo Group Inc., EAM Investors LLC, First Trust Advisors LP and Renaissance Technologies LLC. View Insider Buying and Selling for Amedisys.
How do I buy shares of Amedisys?
Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amedisys' stock price today?
One share of AMED stock can currently be purchased for approximately $117.23.
How big of a company is Amedisys?
Amedisys has a market capitalization of $3.63 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.
How can I contact Amedisys?
Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]
MarketBeat Community Rating for Amedisys (NASDAQ AMED)
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
